Huahai Pharmaceutical secures registration for hemostasis injection

Zhejiang Huahai Pharmaceutical Co., Ltd. recently obtained a drug registration certificate from the National Medical Products Administration for Carbazochrome Sodium Sulfonate Injection. The drug, a Category 3 chemical medicine for domestic production, is available in 5ml:25mg specifications and is approved under registration number H20255532. This approval is expected to enrich the company's product line and enhance its market competitiveness.

Carbazochrome Sodium Sulfonate Injection is used for hemorrhagic diseases in the urinary system, upper digestive tract, respiratory tract, and obstetrics and gynecology, and is also effective in preventing and treating surgical bleeding. Originally developed by Japan's Tanabe Seiyaku Co., Ltd. and launched in 1957, the drug's domestic market for 2024 is projected to reach approximately 250 million yuan.

Huahai Pharmaceutical has invested approximately 712,000 yuan in the research and development of Carbazochrome Sodium Sulfonate Injection. The company emphasizes its commitment to quality and safety in all stages of drug development, production, and sales. Investors are advised to exercise caution due to potential market and policy uncertainties impacting product manufacturing and sales.